المؤلفون: Howard West, Christian D. Rolfo, Silvia Novello, Jordi Remon, Tanja Cufer, Nir Peled, Normand Blais, Giannis Mountzios, Johan Vansteenkiste, Benjamin Besse, Stephen V. Liu, Raffaele Califano, A. M. Dingemans, Nathan A. Pennell, Martin Reck, D.S.W. Tan

المساهمون: RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Pulmonologie, Pulmonary Medicine

المصدر: Annals of oncology, vol. 30, no. 11, pp. 1686-1688, 2019.
Annals of Oncology, 30(11), 1686-1688. Oxford University Press
Annals of Oncology, 30(11), 1686-1688. Elsevier Ltd.

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Standard of care, Lung Neoplasms, KEYNOTE-042, pemrolizumab, Pembrolizumab, PD-L1≥1%, non-small cell lung cancer, pembrolizumab, Antibodies, Monoclonal, Humanized, B7-H1 Antigen, Disease-Free Survival, KEYNOTE-024 trial, Food and drug administration, non-small cell lung carcinoma, SDG 3 - Good Health and Well-being, Internal medicine, Carcinoma, Non-Small-Cell Lung, Carcinoma, medicine, Humans, Progression-free survival, terapija z zdravili, Lung cancer, Drug Approval, udc:616.2, Randomized Controlled Trials as Topic, DOCETAXEL, treatment, business.industry, United States Food and Drug Administration, nedrobnocelični karcinom pljuč, NIVOLUMAB, Standard of Care, zdravljenje, Hematology, medicine.disease, Progression-Free Survival, United States, drug therapy, raziskava KEYNOTE-024, Pd l1 expression, Non small cell, business, 1ST-LINE

وصف الملف: application/pdf; text/url; Print

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::baa656a081347a69a9326aacdbaa841a
https://dirros.openscience.si/Dokument.php?id=14984&dn=